{
    "clinical_study": {
        "@rank": "8399", 
        "arm_group": {
            "arm_group_label": "IVR group"
        }, 
        "brief_summary": {
            "textblock": "The investigators compared the time to recurrence after ranibizumab or aflibercept loading\n      in patients with AMD."
        }, 
        "brief_title": "Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept", 
        "condition": "The Injection Burden", 
        "condition_browse": {
            "mesh_term": [
                "Macular Degeneration", 
                "Recurrence"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  They must have had BCVA better than 20/400 and had three consecutive induction\n             treatment of ranibizumab or aflibercept.\n\n        Exclusion Criteria:\n\n          -  patients with eye diseases that could potentially influence the visual acuity of the\n             studied eye, such as glaucoma, macular hole, diabetic retinopathy, or rhegmatogenous\n             retinal detachment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All the patients were treated at Yokohama City University Medical Center between January\n        2012 and October 2013."
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02126904", 
            "org_study_id": "1310006"
        }, 
        "intervention": {
            "arm_group_label": "IVR group", 
            "intervention_name": "IVA group", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "contact": {
                "email": "maicoo@urahp.yokohama-cu.ac.jp", 
                "last_name": "Maiko Inoue, M.D.", 
                "phone": "81 45 261 5656", 
                "phone_ext": "7458"
            }, 
            "facility": {
                "address": {
                    "city": "Yokohama", 
                    "country": "Japan", 
                    "state": "Kanagawa", 
                    "zip": "232-0024"
                }, 
                "name": "Yokohama City University Medical Center"
            }, 
            "investigator": {
                "last_name": "Maiko Inoue, M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Time frame depends on patients because recurrence time is different.", 
            "measure": "Time to recurrence after induction phase", 
            "safety_issue": "Yes", 
            "time_frame": "More than 3 months from baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02126904"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yokohama City University Medical Center", 
            "investigator_full_name": "Maiko Inoue", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Yokohama City University Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Yokohama City University Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}